Menin is an epigenetic regulatory protein that plays a key role in beta-cell proliferation and function, as previously demonstrated though increased beta-cell mass generation in Men1 knockout mice (Ja et al., 2021;13 (5) :e13524) . Here, we demonstrate the marked potential of an oral menin inhibitor, BMF-219, in durable glycemic control following a short course treatment in a Type 2 Diabetes Mellitus (T2DM) Zucker Diabetic Fatty Rat model. Rats were treated daily with BMF-219, liraglutide or vehicle for 28 days and monitored for an additional 28 days post-treatment. All animals tolerated BMF-219 well throughout the study. Notably, BMF-219 treatment resulted in a significant reduction in HbA1C at Day 21, which reached 3.5% absolute reduction in HbA1C versus vehicle, compared to liraglutide (1.7% reduction) at Day 29 and remained reduced throughout the entire study, including post-treatment. The high-dose arm of BMF-219 showed a strong reduction in 4-hour fasting blood glucose during the treatment up to Day 29. Both BMF-219 dose groups showed improved glycemic control by oral glucose tolerance test (OGTT) on day 25, in contrast to vehicle and liraglutide-treated animals. Additionally, insulin levels, HOMA-IR, HOMA-B, OGTT, HbA1C, and C-peptide levels measured at Day 57 across all groups will be reported. Collectively, these data demonstrate the novel long-acting potential of BMF-219 as an oral treatment for T2DM, in maintaining glycemic control after short-term dosing.

graphic
View largeDownload slide
Disclosure

P. Somanath: Employee; Biomea Fusion, Inc., Stock/Shareholder; Biomea Fusion, Inc. M. Balakrishnan: Employee; Biomea Fusion, Inc., Other Relationship; Gilead Sciences, Inc., Stock/Shareholder; Biomea Fusion, Inc., Gilead Sciences, Inc. T. Butler: Employee; Biomea Fusion Inc. S. Mourya: Employee; Biomea Fusion, Stock/Shareholder; Ascendis Pharma A/S. W. Li: None. T. C. Archer: Employee; Biomea Fusion. B. Law: Stock/Shareholder; Biomea Fusion Inc., Mirum Pharmaceuticals. D. Lu: Employee; Biomea Fusion Inc., Stock/Shareholder; AbbVie Inc. T. Rughwani: None. L. Kumar: None. T. Kinoshita: None.

© 2022 by the American Diabetes Association
2022
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.